QNRX - Why Quoin Pharmaceutical Stock Is Soaring | Benzinga
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) shares are trading higher Monday after the company announced it has obtained FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies.
The Details:
Quoin announced clearance from the U.S. Food and Drug Administration (FDA) to recruit teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being developed as a potential treatment for Netherton Syndrome.
“We are very pleased to announce this exciting development, not just for Quoin’s clinical program, but for the Netherton community as a whole. We are frequently petitioned by parents ...